Sanofi India Q2CY25 FY24 – Pharma Maharaja with 47% ROE, -30% 1Y Return, and a Goa Factory Churning 5 Billion Pills: Genius or Just Overdosed?
1. At a Glance
Ladies and gentlemen, here’s Sanofi India — a French multinational’s Indian avatar that makes insulin needles sharper than your HR’s appraisal excuses. Market cap: a respectable ₹11,527 crore. Price per share: ₹5,002, which is basically an EMI for an iPhone 16 Pro Max. P/E ratio? 32.3 — pharma industry median is 34, so it’s like that kid who doesn’t top the class but still gets free tuition because papa is a diplomat. Return on Equity? 47.2% — so efficient they could probably manufacture glucose out of sarcasm.
But here’s the spicy bit: stock is down -30% in 1 year. Imagine scoring 97/100 in exams and still being grounded. Why? Because sales growth over the last 5 years is -8.1% and profits haven’t moved an inch in 5 years. Classic gym bro stock — looks ripped (ROE, ROCE flex), but can’t run more than 200 meters (topline growth).
So, is this the pharma aristocrat delivering miracles or just a high-ROE nostalgia brand milking Allegra ads from the 2000s? Let’s dissect.
2. Introduction
Sanofi India is that NRI cousin who visits every two years, brings Toblerone from duty-free, and lectures you about healthcare reforms in Europe while refusing to eat pani puri. Globally, Sanofi is a pharma powerhouse, but in India? It’s somewhere between “premium French perfume” and “your neighborhood chemist who’s sick of explaining why Allegra doesn’t work for COVID.”
Once upon a time, Sanofi was considered a “must-own MNC pharma stock.” It had insulin leadership, a brand portfolio that made competitors jealous, and a dividend payout ratio of 113% — yes, they literally pay out more than they earn sometimes, like that uncle who spends more on weddings than his salary.
But the recent years have been Bollywood-level dramatic. Divestments of manufacturing units, spinning off its consumer health division, fighting price caps under NLEM, and watching new-age desi competitors like Mankind and Zydus dance away with market share.
Yet, Sanofi’s Goa plant still cranks out over 5 billion tablets annually, and the company maintains margins north of 25%. It’s like Virat Kohli scoring centuries in bilateral series while the team keeps losing ICC knockouts. Respectable but frustrating.
Do you think high ROE is enough if sales growth is flat? Or is Sanofi just a dividend aristocrat in a midlife crisis?
3. Business Model – WTF Do They Even Do?
Sanofi India’s business is basically three-tiered:
Therapeutic Focus: Diabetes, Cardiology, Neurology, Thrombosis, and Antihistamines. Translation: stuff that either keeps you alive longer or helps you sneeze less.
Flagship Brands: Lantus (insulin), Allegra (anti-histamine), Ramipril (BP), Depakine (neurology), and Toujeo (insulin again). Think of it as a Spotify playlist for chronic diseases.
Distribution: 3,000 distributors + 1 lakh pharmacies. Even Amul doodh packets don’t have this kind of reach.
But here’s the masala:
81% revenue comes from India. Exports make up 19%, with Singapore chipping in 18% alone. Basically, Singapore sneezes, Sanofi India catches cold.
Single customer concentration? 18% of revenue. That’s like having one client on Upwork who decides your entire month’s rent.
On the manufacturing side, Goa plant = Sanofi’s personal Dosa Plaza. Authorized globally (outside Frankfurt) to make Ramipril PC granules. But they divested their nutraceuticals (₹587 cr) and Ankleshwar facility earlier. It’s like selling your cricket kit but claiming you’ll still score centuries.
So yes, they’re still making drugs, but the model looks more like “selective, margin-heavy, and French-level premium.” Not exactly the Reliance Jio of pharma.
4. Financials Overview
Here’s the scorecard for Jun’25 quarter vs last year and last quarter:
